Kanuma

Sebelipase Alfa, the active ingredient in Kanuma, is an enzyme replacement therapy presented as a solution for intravenous infusion for the treatment of lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease, in pediatric and adult patients.\n\nGNH India supplies Kanuma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kanuma is an enzyme replacement therapy indicated for lysosomal storage disorders that involve deficient acid lipase activity.\n\nLysosomal acid lipase deficiency (LAL‑D): reduces lipid accumulation in liver and vessels, improving organ function.\nWolman disease: provides functional enzyme to mitigate severe infantile disease manifestations.\nCholesteryl ester storage disease: restores enzyme activity to lower cholesterol ester and triglyceride storage in tissues.

Common Side Effects:\n- Infusion‑related reactions such as flushing, chills, or fever.\n- Gastrointestinal symptoms including nausea, abdominal pain, or vomiting.\n- Headache or fatigue during or after infusion.\n\nSerious or Rare Side Effects:\n- Anaphylaxis or severe hypersensitivity reactions requiring immediate medical attention.\n- Significant elevations in liver enzymes indicating hepatic stress.\n- Thrombocytopenia or other hematologic abnormalities observed in rare cases.

Kanuma requires careful monitoring and specific handling precautions.\n\nInfusion monitoring: observe patients for reactions during and after administration.\nLiver function: assess baseline and periodic hepatic enzymes.\nImmunogenicity: monitor for development of anti‑drug antibodies with repeated dosing.\nPediatric use: dosing and safety have been established in children with LAL‑D.\nPregnancy and lactation: use only if potential benefits justify potential risks; data are limited.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanuma may interact with other therapies that affect immune response or share infusion pathways.\n\nMajor Interactions (Avoid):\n- Concomitant live vaccines: may reduce vaccine efficacy.\n- Strong immunosuppressants: may increase infection risk.\n- Other enzyme replacement therapies: may cause overlapping infusion reactions.\n\nModerate Interactions (Monitor Closely):\n- Antihistamines: may mask infusion‑related symptoms.\n- Corticosteroids: may be used to manage infusion reactions but require monitoring.